AEON Biopharma
AEON
37 hedge funds and large institutions have $4.8M invested in AEON Biopharma in 2024 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 1 closing their positions.
700% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 1
23% more funds holding
Funds holding: 30 → 37 (+7)
0.03% less ownership
Funds ownership: 0.34% → 0.31% (-0.03%)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
52% less capital invested
Capital invested by funds: $10.1M → $4.8M (-$5.25M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FAM
Formidable Asset Management
Cincinnati,
Ohio
|
+$242K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$40.4K |
| 3 |
VF
Virtu Financial
New York
|
+$30.7K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$19.9K |
| 5 |
HF
HRT Financial
New York
|
+$16.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$677K |
| 2 |
BOCH
Blue Owl Capital Holdings
New York
|
-$236K |
| 3 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
-$12.5K |
| 4 |
Two Sigma Investments
New York
|
-$9.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$7.11K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BP
26
BBR Partners
New York
| $6.26K | – | – | – |
|
27
Jane Street
New York
| $5.95K | +$233 | +4 | +3% |
|
28
Morgan Stanley
New York
| $5.87K | +$7.34K | +126 | +504% |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| $4.53K | +$2.56K | +44 | +60% |
|
|
SPIA
30
Steward Partners Investment Advisory
New York
| $4.43K | +$815 | +14 | +14% |
|
31
Wells Fargo
San Francisco,
California
| $3.51K | +$5.24K | +90 | New |
|
|
WWM
32
Wolff Wiese Magana
Carslbad,
California
| $2.61K | +$3.9K | +67 | New |
|
|
MCM
33
MAI Capital Management
Independence,
Ohio
| $2.29K | +$3.44K | +59 | New |
|
|
GIA
34
GHP Investment Advisors
Denver,
Colorado
| $592 | – | – | – |
|
35
CIBC Private Wealth Group
Atlanta,
Georgia
| $459 | – | – | – |
|
|
SS
36
SBI Securities
Tokyo,
Japan
| $56 | +$58 | +1 | New |
|
37
JP Morgan Chase
New York
| $29 | – | – | – |
|
|
38
Cetera Investment Advisers
Schaumburg,
Illinois
| – | -$12.5K | -166 | Closed |
|
AEON Hedge Fund Activity: Q4 2024 in Review
37 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q4 2024, worth a combined $4.8M — down 52% from $10.1M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new AEON positions and 1 closed out — a net gain of 7 holders — while 8 added to existing stakes and 9 trimmed.
The largest buyer was Formidable Asset Management, adding an estimated $242K. The largest seller was Polar Asset Management Partners, cutting an estimated $677K.
- 37 institutional investors held AEON Biopharma (AEON) as of Q4 2024, up from 30 in Q3 2024.
- Funds reported $4.8M of AEON Biopharma stock for Q4 2024, down 52% quarter-over-quarter.
- 8 funds opened new AEON Biopharma positions in Q4 2024 and 1 closed out, a net change of +7 holders.
- The largest AEON Biopharma buyer in Q4 2024 was Formidable Asset Management, an estimated $242K added.
- The largest AEON Biopharma seller in Q4 2024 was Polar Asset Management Partners, an estimated $677K sold.
Based on aggregated 13F filings for Q4 2024.